ATRYS HEALTH, S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.13 EUR | +7.93% |
|
+7.93% | -14.71% |
| 26/03 | Atrys Health, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Atrys Health, S.A. announced that it has received ?13.3 million in funding | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 113.2 | 298.6 | 621 | 456.6 | 278.4 | 237.7 | - | - |
| Enterprise Value (EV) 1 | 112 | 341 | 695.8 | 574.1 | 278.4 | 402.9 | 368.7 | 350.7 |
| P/E ratio | -1,000 x | -125 x | -22.1 x | -18.2 x | -6.11 x | -76.1 x | 17.1 x | 17.1 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 7.63 x | 9.51 x | 5.13 x | 2.44 x | 1.38 x | 1.07 x | 1 x | 0.93 x |
| EV / Revenue | 7.55 x | 10.9 x | 5.75 x | 3.07 x | 1.38 x | 1.82 x | 1.55 x | 1.37 x |
| EV / EBITDA | 21.9 x | 57.5 x | 120 x | 25.9 x | 6.54 x | 8.77 x | 6.79 x | 6.05 x |
| EV / FCF | - | -7.73 x | -180 x | - | - | 12.6 x | 13.1 x | - |
| FCF Yield | - | -12.9% | -0.56% | - | - | 7.92% | 7.65% | - |
| Price to Book | 3.2 x | 4.09 x | 2.27 x | 1.39 x | - | 0.77 x | 0.57 x | - |
| Nbr of stocks (in thousands) | 22,632 | 33,545 | 61,178 | 73,638 | 75,851 | 75,934 | - | - |
| Reference price 2 | 5.000 | 8.900 | 10.15 | 6.200 | 3.670 | 2.900 | 2.900 | 2.900 |
| Announcement Date | 31/03/20 | 27/04/21 | 30/03/22 | 29/03/23 | 26/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 14.84 | 31.4 | 121 | 187 | 201.6 | 221.4 | 237.5 | 256 |
| EBITDA 1 | 5.11 | 5.932 | 5.783 | 22.14 | 42.59 | 45.93 | 54.3 | 58 |
| EBIT 1 | 1.215 | 5.673 | -15 | -8.204 | 12.92 | 14.51 | 29.8 | 28 |
| Operating Margin | 8.19% | 18.07% | -12.4% | -4.39% | 6.41% | 6.55% | 12.55% | 10.94% |
| Earnings before Tax (EBT) 1 | 0.2066 | -1.309 | -24.88 | -24.69 | -33.7 | -3.194 | 5 | 17 |
| Net income 1 | - | -2.015 | -23.26 | -23.26 | -45.59 | 2.12 | 8.35 | 13 |
| Net margin | - | -6.42% | -19.22% | -12.44% | -22.62% | 0.96% | 3.52% | 5.08% |
| EPS 2 | -0.005000 | -0.0710 | -0.4600 | -0.3410 | -0.6010 | -0.0381 | 0.1700 | 0.1700 |
| Free Cash Flow 1 | - | -44.08 | -3.873 | - | - | 31.9 | 28.2 | - |
| FCF margin | - | -140.41% | -3.2% | - | - | 14.41% | 11.87% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | 69.46% | 51.93% | - |
| FCF Conversion (Net income) | - | - | - | - | - | 1,504.59% | 337.72% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 31/03/20 | 27/04/21 | 30/03/22 | 29/03/23 | 26/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|
| Net sales | - | - | - | - |
| EBITDA 1 | 17.38 | - | 22.65 | 16.85 |
| EBIT 1 | -0.091 | -8.113 | 5.779 | 4.054 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) | -4.379 | -20.31 | - | - |
| Net income 1 | -3.166 | -20.09 | -23 | -22.59 |
| Net margin | - | - | - | - |
| EPS | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 30/09/22 | 29/03/23 | 29/09/23 | 26/03/24 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 42.4 | 74.9 | 118 | - | 165 | 131 | 113 |
| Net Cash position 1 | 1.19 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 7.148 x | 12.95 x | 5.309 x | - | 3.598 x | 2.413 x | 1.948 x |
| Free Cash Flow 1 | - | -44.1 | -3.87 | - | - | 31.9 | 28.2 | - |
| ROE (net income / shareholders' equity) | 5.68% | -3.5% | -13.5% | -7.61% | - | -0.09% | 3.6% | 4.4% |
| ROA (Net income/ Total Assets) | - | 1.32% | - | -3.66% | - | - | 0.7% | 2.2% |
| Assets 1 | - | -152.8 | - | 635.5 | - | - | 1,193 | 590.9 |
| Book Value Per Share 2 | 1.560 | 2.170 | 4.470 | 4.450 | - | 3.780 | 5.130 | - |
| Cash Flow per Share 2 | 0.0500 | 0.2800 | 0.0900 | -0.2300 | - | 0.3400 | - | - |
| Capex 1 | - | 52.1 | 8.57 | 15.2 | - | 16 | 12.5 | 12 |
| Capex / Sales | - | 165.89% | 7.08% | 8.11% | - | 7.23% | 5.26% | 4.69% |
| Announcement Date | 31/03/20 | 27/04/21 | 30/03/22 | 29/03/23 | 26/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.9
EUR
Average target price
6.61
EUR
Spread / Average Target
+127.93%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.71% | 237M | |
| +20.68% | 84.31B | |
| -29.31% | 69.9B | |
| +9.65% | 29.06B | |
| -8.63% | 17.38B | |
| +2.14% | 17.01B | |
| +0.39% | 15.35B | |
| +6.47% | 12.91B | |
| +68.23% | 12.47B | |
| +6.43% | 12.26B |
- Stock Market
- Equities
- ATRY Stock
- Financials Atrys Health, S.A.